There are currently 807 clinical trials in Detroit, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Henry Ford Hospital, Henry Ford Health System, Barbara Ann Karmanos Cancer Institute and Karmanos Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
NCT05177107
Recruiting
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
09/05/2023
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Register for Updates
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285
Recruiting
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Covid19
Register for Updates
Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study
NCT04080427
Recruiting
The goal of this study is to look at how a type of drug called cannabinoids are related to the processing of fear signals, the experience of emotions and fear, and the pattern of activity in the brain that is involved in these processes and how this relates to the treatment of post-traumatic stress disorder (PTSD). PTSD is an anxiety disorder that occurs after experiencing a traumatic event(s) and is characterized by unwanted memories of the trauma(s) through flashbacks or nightmares, avoidance... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
07/12/2023
Locations: Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan
Conditions: Posttraumatic Stress Disorder
Register for Updates
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Recruiting
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
NCT03797391
Recruiting
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Register for Updates
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Detroit, Michigan
Conditions: Solid Tumor, NSCLC
Register for Updates
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
NCT03453489
Recruiting
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2023
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Conditions: Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Register for Updates
DOAC in Unusual Site Venous Thrombosis
NCT03778502
Recruiting
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/20/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Detroit, Michigan
Conditions: Cystic Fibrosis
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: HER2-negative Breast Cancer
Register for Updates
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
NCT05210582
Recruiting
The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2023
Locations: CLINUVEL Investigational site, Detroit, Michigan
Conditions: Vitiligo
Register for Updates
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
NCT03941366
Recruiting
The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/30/2023
Locations: Ascension St. John Hospital, Detroit, Michigan
Conditions: Rectal Cancer
Register for Updates